The service — which Seegene plans to launch next year — boasts the specificity of fluorescently tagged probes at the cost of intercalating dyes.
Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.
The worldwide collaboration agreement is for co-development of multiplex real-time PCR reagents for the BD Max molecular diagnostics platform.
Seegene will develop a menu of multiplex assay panels, initally in the area of infectious disease, for Qiagen's QIAsymphony RGQ molecular diagnostics platform.
The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.
The South Korean molecular diagnostics firm plans to grow its global market presence and pursue FDA approval for its products from Seegene Technologies, its new base in California.
The molecular diagnostic test identifies influenza virus A subtypes H1 and H3, influenza B, and human respiratory syncytial viruses A and B.
The test uses the company's TOCE primer technology for multiplexed real-time PCR and is the first product Seegene has taken through the FDA.
Trends included expanding test menus and a possible tipping point for point-of-care.
Seegene will manufacture reagents designed exclusively for Beckman Coulter's new Veris MDx sample-to-answer molecular diagnostics system.
In Nature this week: genetic history of HIV in the US, and more.
There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.
A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.
Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.